Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

To report the results of the DECT trial, a phase II study of locally advanced or operable HER2‐positive breast cancer (BC) treated with taxanes and concurrent anthracyclines and trastuzumab. Eligible patients (stage IIA‐IIIB HER2‐positive BC, 18–75 years, normal organ functions, ECOG ≤1, and left ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzuti, Laura, Barba, Maddalena, Giannarelli, Diana, Sergi, Domenico, Botti, Claudio, Marchetti, Paolo, Anzà, Michele, Maugeri‐Saccà, Marcello, Natoli, Clara, Di Filippo, Simona, Catenaro, Teresa, Tomao, Federica, Amodio, Antonella, Carpano, Silvia, Perracchio, Letizia, Mottolese, Marcella, Di Lauro, Luigi, Sanguineti, Giuseppe, Di Benedetto, Anna, Giordano, Antonio, Vici, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089631/
https://www.ncbi.nlm.nih.gov/pubmed/27187274
http://dx.doi.org/10.1002/jcp.25432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089631/
https://www.ncbi.nlm.nih.gov/pubmed/27187274
http://dx.doi.org/10.1002/jcp.25432

Ejemplares similares